An Introduction to Sarcoma
Sarcomas are a heterogeneous group of mesenchymal malignancies, with more than 50 subtypes identified. Until recently treatment was limited to standard chemotherapy regimens, however, advances in next-generation sequencing technology have led to the development of molecularly targeted therapy and immunotherapy that offer a personalized treatment approach.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches
touchREVIEWS in Oncology & Haematology.2022;18(1):73–7 DOI: https://doi.org/10.17925/OHR.2022.18.1.73
Sarcomas are a diverse group of rare muscle, bone and connective tissue tumours. Within soft-tissue sarcoma alone, there are over 70 subtypes, which demonstrate substantial heterogeneity in biology, genetics and clinical behaviour.1 Further complicating their management is the range of treatment responsiveness, with some subtypes wholly refractory to traditional chemotherapy, while others are quite responsive to […]
Brian Van Tine, ASCO 2021: Findings from the APROMISS Study
We were delighted to talk with Dr Brian Van Tine (Washington University School of Medicine, Saint Louis, MO, US) around the APROMISS study, investigating the efficacy and safety of AL3818 hydrochloride monotherapy in patients with metastatic or advanced synovial sarcoma. The abstract ‘A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects […]
Pexidartinib and CSF1R Inhibitors as Treatment for Tenosynovial Giant Cell Tumors
Oncology & Hematology Review (US). 2020;16(2):119-23 DOI: https://doi.org/10.17925/OHR.2021.16.2.119
Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This review serves to discuss the epidemiology, molecular biology, clinical behavior, and the current treatment modalities of TGCT that […]
Pazopanib in Soft Tissue Sarcomas
Oncology & Hematology Review (US). 2020;16(1):15–6 DOI: https://doi.org/10.17925/OHR.2020.16.1.15
Soft tissue sarcomas represent a group of over 80 rare malignant tumors that arise from tissues of mesenchymal origin throughout the body.1 Advanced soft tissue sarcoma is treated with single-agent or combination systemic chemotherapy, but is associated with a poor prognosis.2,3 Pazopanib (Votrient,® Novartis, Basel, Switzerland) is an oral multitarget tyrosine kinase inhibitor that has received regulatory as […]
Expert interview with Jonathan Trent: Immunotherapy of GISTs
Professor Jonathan Trent MD, PhD is Associate Director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida, USA. In this interview, he discusses the challenging state of the art of immunotherapy of gastrointestinal stromal tumors (GISTs) today and the clinical usefulness of profiling “wild-type” GIST. He discussed this […]
Paolo A. Ascierto – spotlight interview
Professor Paolo A. Ascierto is Director of the Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute, Naples, Italy. He obtained his medical degree from the University of Naples, the same institution where he subsequently earned his board certification in oncology. He went on to serve consecutive positions at the National […]
Brian Van Tine, ESMO 2019 – Pazopanib in soft tissue sarcomas
Brain Van Tine (Washington University in St Louis) joins us to discuss the results of the phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy (NCT02300545). Questions 1. What are the limitations of standard first-line chemotherapy in the treatment of soft […]
Alona Zer, ASCO 2019 – Phase II study of nivolumab and ipilimumab in CKS
At the ASCO 2019 annual meeting, Alona Zer discusses the preliminary results from the interim analysis of a phase II study of nivolumab and ipilimumab in previously treated progressive Classic Kaposi Sarcoma (CKS) (NCT03219671). Questions 1. Could you tell us a little about Classic Kaposi Sarcoma (CKS) and its prognosis? (0:04) 2. What is the […]
Advanced soft tissue sarcoma – how can we address current controversies to solve a dilemma in clinical decision making?
Watch a panel of internationally renowned experts discuss the factors influencing the choice of first-line treatment for patients with advanced soft tissue sarcoma and the interpretation of data from clinical trials in this patient population.
- Describe first-line treatment options for patients with advanced soft tissue sarcoma (STS)
- Understand how patient selection may affect treatment choice and outcome in advanced STS
- Discuss how surrogate markers can be used in trial design to assess treatment outcomes in advanced STS
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!